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Inhaled steroid therapy is the most important treatment in the management of chronic asthma and currently 
twice-daily administration is recommended in mild to moderate asthma. Compliance is often a problem in 
asymptomatic patients and may lead to reduced disease control. ‘\, 
Our aim was to investigate whether budesonide 0.2 mg once daily administered via the Turbuhaler is as effective 
as 0.1 mg twice daily. 
A randomized, double-blind, parallel group study was carried out in which 76 adult patients with mild to 
moderate asthma (FEV, 86% of predicted) were allocated to budesonide once or twice daily. After a run-in period 
of 2 weeks on present inhaled steroid treatment (0.2-0.5 mg day ~ ‘) there was an 8 week treatment period, followed 
by a washout period in which patients received no steroid for 4 weeks unless a drop in morning peak flow of at least 
20% occurred or the use of &agonists increased by 50%. 
Both treatment groups improved minimally in peak flow (1.7 and 4.3 1 min ~ ’ in the once-daily and twice-daily 
groups respectively) but the differences between the two groups were not significant. Testing the reverse hypothesis 
revealed clinical equivalence. The 90% confidence interval of the difference in the change of peak flow from run-in 
was between + 30 and - 30 1 min - ‘, the limits deemed to be clinically relevant. There were no differences in 
symptom scores, &agonist use or spirometry measurements between the two groups. In the washout period there 
was a significant deterioration in peak flow and symptoms. 
This study shows that 0.2 mg budesonide given once a day is as affective as 0.1 mg given twice daily in patients 
with mild to moderate asthma. 
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Introduction 
Inhaled corticosteroid therapy is recognized as the most 
important treatment in the management of chronic asthma 
(1,2). In severe asthma, a high dosage is necessary but in 
patients with mild or moderate disease a lower dosage, 
usually 0.4 mg day- ‘, is often sufficient. 
In mild asthma, patients may be asymptomatic or almost 
asymptomatic but the inflammatory processes are still 
present in the airways (3). Thus, regular anti-inflammatory 
treatment is necessary but in such patients compliance may 
be a problem. A decrease in the frequency of drug admin- 
istration is more convenient and can improve compliance 
in these patients (4). Currently, in moderate asthma 
twice-daily administration of inhaled steroids is generally 
recommended but in severe asthma four times daily treat- 
ment may be necessary (5,6). One other study showed that 
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in moderate asthma twice-daily dosage of budesonide 
Turbuhaler was just as effective as four times daily 
(0.4 mg day ~ ‘) (7). However, few studies have investigated 
a further decrease to once daily. One study showed budeso- 
nide inhaled by Turbuhaler (0.4 mg day - ‘) given in the 
evening was superior to placebo when used as an initial 
treatment in mild asthma in patients who had previously 
received no inhaled steroids (8). Another study showed no 
difference in the efficacy of once-daily (morning or evening) 
or twice-daily budesonide inhaled by Turbuhaler (0.4 mg 
day - ‘) as initial treatment for asthma (9). Only one recent 
study showed that in moderate asthma twice-daily budeso- 
nide, given via pressurized metered dose inhaler (pMDI), 
gave better clinical control than a once-daily regimen 
(0.8 mg day ~ ‘), but without significant difference in effect 
on peak flow (10). A study comparing beclomethasone 
diproprionate once daily (0.25 mg day - ‘) with three times 
daily (0.2-0.3 mg day - ‘) showed the higher frequency to 
be superior to the once-daily dosage (11). 
Drug deposition in the lungs varies depending on the 
type of device used and Turbuhaler is capable of delivering 
double the fraction of respirable drug particles when com- 
pared with a pMD1 (12,13), thereby facilitating a dose 
reduction by 50% (14). Therefore, using a daily dose of 
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0.2 mg budesonide by Turbuhaler may be sufficient in the 
mild asthmatic patient. 
Since there is no general agreement on whether a single 
daily dose is sufficient as a maintenance treatment in 
patients with mild to moderate asthma already treated with 
an inhaled steroid we aimed to investigate whether the 
efficacy of budesonide, administered via Turbuhaler in a 
daily dosage of 0.2 mg, is the same when given once or 
twice daily. 
Method 
PATIENTS 
Patients aged 18-70 years with a diagnosis of asthma (1,2) 
currently using an inhaled steroid in a dosage of between 0.2 
and 0.5 mg per day, unchanged for at least 2 months prior 
to study entry, were eligible for inclusion. All patients were 
recruited from 16 general practices in The Netherlands and 
monitored during the study by their general practitioner. 
Other criteria included a prebronchodilator FEV, above 1 1 
and a postbronchodilator PEF and FEV, above 70% of the 
predicted normal value (15). Patients were excluded if they 
had had an acute exacerbation of asthma or a lower respir- 
atory tract infection less than 2 months before the start of 
the study or if they had any significant respiratory or other 
disease that could affect the study. Women who were 
pregnant, considering pregnancy or breastfeeding were also 
excluded. The use of long-acting &-agonists and other 
inhaled or oral steroids was also precluded. 
The permission of the Ethics Commission of Leiden 
Academic Hospital was obtained. All patients gave written 
and verbal informed consent. 
STUDY DESIGN 
This was a randomized, double-blind, parallel group study. 
There was a run-in period of 2 weeks in which patients 
continued their current steroid treatment. There followed a 
double-blind treatment period of 8 weeks in which patients 
were randomly allocated to treatment with budesonide 
0.2 mg in the morning and placebo in the evening (once- 
daily group) or budesonide 0.1 mg twice a day (twice-daily 
group) administered by Turbuhaler (Astra Draco, Lund, 
Sweden). Separately labelled morning and evening Turbu- 
halers were used. The study finished with a steroid-free 
washout period of 4 weeks during which time the patient’s 
need for inhaled steroids was assessed. Patients resumed 
their original inhaled steroids if they had a deterioration in 
their peak flow of 20% or if a 50% increase of their 
requirement for inhaled &agonists over 3 days occurred, 
relative to the values in the last 14 days in the treatment 
period. Patients kept a diary twice a day throughout the 
study and recorded peak flow using the Vitalograph peak 
flow meter (absolute scale) (Vitalograph, Buckingham, 
U.K.), asthma symptoms such as wheezing, shortness of 
breath and cough (score: 0, none; 3, severe) and their 
requirement for their inhaled &-agonist or ipratropium. In 
addition, the use of the study drug and any other prescribed 
medication, the dose and the reason for use was recorded. 
Patients were told to avoid using inhaled bronchodilators in 
the 6 h before and to use the medication after the peak flow 
measurement. Peak flow was measured standing three times 
and the highest reading recorded. The patient visited the 
doctor five times during the study approximately every 4 
weeks at which time spirometry was performed using a 
turbine spirometer (Microlab 3300, Sensor Medics, 
Bilthoven, The Netherlands), the normal values calculated 
according to the ECCS values (15). Information regarding 
drug use, symptoms and side-effects was gathered and guid- 
ance over the use of the peak flow meter and Turbuhaler 
was given by the general practitioner. Patients were 
instructed to fill in the diary completely but primarily 
honestly. The GPs were instructed and visited regularly by 
one of us (S.L.C.) to ensure adherence to the protocol. 
STATISTICAL ANALYSIS 
The primary parameter was the mean morning peak flow 
over the last 14 days of the treatment period. Secondary 
parameters were the evening diary peak flow, &agonist 
use, symptoms score and the (spirometer) peak flow (PEF), 
FEV, and FVC (both absolute and as percentage of pre- 
dicted). The analysis was performed on all randomized 
patients who had at least eight morning peak flow measure- 
ments during the run-in period for comparison with the 
treatment period. Two-weekly mean data prior to the visits 
were analysed. All treatment effects except adverse events 
were estimated by least-squares estimation and tested by 
two-way lay-out analysis of variance in which centre and 
treatment were factors. Paired t-tests were performed to 
estimate steroid responsiveness: mean diary data during the 
last 2 weeks of blind treatment were compared with those 
during the last 14 days (minimally 7 days) prior to resuming 
inhaled steroid treatment. For the morning peak flow 
measurements the reverse hypothesis (that the two treat- 
ments are different) was tested and an equivalence analysis 
was performed. For this we assumed that a difference 
between treatments of a change in peak flow of at least 30 1 
min-’ was clinically relevant. It was tested whether the 
90% confidence interval did contain this 30 1 min - ’ value in 
either direction. 
Results 
Of the 8 1 patients who took part in the study, 70 completed 
it and 11 withdrew. Of these 11, five withdrew during the 
run-in period prior to randomization: two withdrawals 
were due to non-adherence to the protocol, one was due to 
the development of a serious adverse event (breast cancer) 
and two chose not to continue with the study. Seventy-six 
patients were randomized, 38 in each treatment group. 
Statistical analysis of efficacy was carried out on 7 1 patients 
because five patients had not enough baseline peak flow 
measurements obtained during the run-in period to calcu- 
late for (two in the once-daily and three with twice-daily 
groups). The characteristics of the patients at the start of 
the study are shown in Table 1. 
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TABLE 1. Characteristics of the randomized patients at their 
inclusion in the study 
0.2 mg 0.1 mg 
once daily twice daily 
Number 
M:F 
Age (years) 
Length (cm) 
FEV, (1) 
FEV, (% predicted) 
PEF (1 min ~ ‘) 
PEF (% predicted) 
Previously inhaled 
steroid dose (mg) 
38 38 
1820 13:25 
41.7 40.3 
170.3 171.3 
2.89 2.87 
86.4 85.7 
391 394 
82.1 85.0 
0.33 0.36 
The demographic data in the two groups were compar- 
able, except that there were more men in the once-daily 
group. Prior to the study, 52 patients had used beclometha- 
sone diproprionate, 28 budesonide and one used fluticasone 
propionate. 
The primary efficacy parameter was the difference in 
change or morning peak flow. During the treatment period 
there was a negligible improvement in peak flow of 1.7 and 
4.3 1 min - ’ in the once- and twice-daily groups respectively 
(Table 2 Equivalence analysis of these results is shown in 
Fig. 1. The difference in change in peak flow from run-in 
between the two groups and the 90% confidence intervals 
around this difference fall within the 30 1 min ’ range, i.e. the 
effects of the treatments can be considered to be equivalent. 
~~~-~~---~---~----r--~----~~- 
Morning PEF Evening PEF 
FIG. 1. Difference between budesonide 0.2 mg once daily 
and 0.1 mg twice daily related to their effects on morning 
and evening PEF as changes from the run-in period. 
Means and 90% confidence intervals are shown; the 
broken lines represent clinically relevant differences. 
The other diary parameters and the other spirometry 
data are shown in Table 2. None of the differences between 
the two treatments is statistically significant. 
The compliance with study medication intake was calcu- 
lated from the number of ‘clicks’ (one click=one dose) 
remaining in each Turbuhaler after it had been returned at 
the end of the treatment period and comparing this number 
with the expected number of ‘clicks’. Mean compliance was 
100% and 117% for the once-daily and twice-daily group 
respectively for the morning Turbuhaler and 103% and 
113% for the evening Turbuhaler, producing average results 
of 102% for the once-daily groups and 115% for the 
twice-daily group. Only 12 patients fell outside the 755125% 
TABLE 2. The change in daily PEF, symptom score, &-agonist use and spirometric FEV, and PEF 
during the treatment period 
0.2 mg once daily 0.1 mg twice daily 
Baseline Change* Baseline Change* 
(mean) ( f SD) (mean) ( f SD> 
(1) Diary results 
Morning PEF (1 min ~ ‘) 
Evening PEF (1 min - ‘) 
P2 use (per day) 
/I2 use (per night) 
Symptoms day (O-3) 
Symptoms night (O-3) 
(2) Spirometry results 
FEV, (1) 
FEV, (% predicted) 
PEF (1 min - ‘) 
PEF (% predicted) 
409 +1.7*57.9 383 +4.3 It 35.3 
420 +3.80 + 51.4 392 +3.3 Et 35.9 
0.32 +0.02 h 0.61 0.47 - 0.21 f 0.55 
0.16 +0.06 f 0.41 0.17 - 0.01 f 0.24 
0.56 - 0.07 f 0.48 0.62 - 0.06 f 0.60 
0.48 +0.02 f 0.51 0.50 - 0.10 f 0.57 
2.89 +0.02 f 0.24 2.64 +0.03 f 0.16 
85.8 +0.19 zt 5.67 80.9 +0.91 f 4.91 
413 + 10.7 It 45.8 396 +11.8 k29.5 
86.8 + 2.20 f 9.45 87.3 + 2.56 i 6.68 
Baseline: diary parameters measured during the run-in period, spirometry data at randomization 
(evaluable subjects). Change: diary parameters measured during last 2 weeks on treatment, 
spirometry data on the visit at week 8. SD: standard deviation. 
*None of the differences between the changes is significant at the level PcO.05. 
424 S. L. CHISHOLM ET AL. 
Discussion 
FIG. 2. The changes in PEF, &agonist use and symp- 
toms during the budesonide washout period in patients 
using no inhaled steroid for at least I days, Means and 
standard error shown. 
range (five below 75% and seven above 125%) four 
and eight from the once-daily and twice-daily groups 
respectively. 
During the double-blind treatment phase of the study five 
patients withdrew, four because of worsening asthma symp- 
toms requiring additional treatment (two in each treatment 
group) and one because of an adverse event, namely 
hoarseness (twice-daily group). One patient withdrew dur- 
ing the washout period owing to a serious adverse event 
(breast cancer, twice-daily group). Except for the two cases 
of breast cancer (one in the run-in period and one in the 
wash-out period) no serious adverse events were reported. 
The most frequently reported adverse events were symp- 
toms of common cold and headache. Coughing after inha- 
lation and hoarseness were reported once; oral candidiasis 
was not observed. 
Sixty-eight evaluable patients entered the washout period 
and, of these, 56 were suitable for statistical analysis (one 
patient withdrew after discovering breast cancer and 11 
patients failed to cease using the inhaled steroid during this 
period). Of these 56 patients, 23 restarted their inhaled 
steroid during the washout period, 13 correctly according to 
the criteria set in the protocol and ten incorrectly. Of the 33 
patients who did not restart their steroid, two fulfilled the 
criteria to restart but failed to do so. During the washout 
period there was a decline in lung function and an increase 
in symptoms and the use of &agonists in patients who used 
no inhaled steroid for at least 7 days (n =48). The decline in 
lung function was almost significant for the morning peak 
flow and there was a significant drop in evening peak flow 
and a significant increase in &agonist use and symptom 
scores for the day and night. These results can be seen in 
Fig. 2. 
The median time until patients restarted their inhaled 
steroid was 10 days (3-24 days) for all patients who 
restarted their medication (n=23) and 8 days (3-24 days) 
for those who correctly followed the protocol (n= 13). The 
remaining 33 patients did not recommence inhaled steroids 
during the washout period. 
This study confirms the hypothesis that budesonide given 
via Turbuhaler in a dose of 0.2 mg once daily is as effective 
as 0.1 mg twice a day in patients with mild asthma. It also 
shows that both regimes are equally well accepted and 
tolerated. 
The lung function of the patients at the beginning of the 
study reflects the fact that only patients with mild to 
moderate asthma were included. The average spirometry 
FEV, was 86% of the predicted value. The patients had on 
average a quite low symptom score and used relatively 
small amounts of &-agonists. This suggests that the 
patients were receiving optimal or almost optimal steroid 
treatment prior to the study (1,2). 
During the treatment period, diary peak flow hardly 
changed in either group and the difference in the change in 
peak flow between the two groups was not significant. 
However, failing to show a difference between two treat- 
ments may be caused by large interindividual differences 
and a too small number of patients, the so called type II 
error. Therefore, the reverse hypothesis was also tested (16), 
considering a predetermined difference in the change of 
peak flow of 30 1 min ~ ’ to be clinically relevant. The result 
of this test indicated that the two treatments can be 
considered to be equivalent. 
In those patients who actually stopped using the inhaled 
steroid, lung function dropped, symptoms increased and 
the use of &agonist doubled. This indicates that we 
selected steroid-responsive asthmatic patients. However, 
within 4 weeks of this washout less than half of these 
patients restarted their inhaled steroid. The remaining 
patients did not fulfil the preset criteria for this restart 
within 4 weeks, but it is not known when or whether these 
patients would need to restart inhaled steroids at some time 
later. Carry-over effect of inhaled steroids may indeed 
persist during several weeks (17). For the equivalence 
analysis, we assumed a difference in the change in peak flow 
of 30 1 min - ’ (approximately 10%) to be clinically relevant. 
However, in the washout period the inhaled steroid was 
reinstituted after a drop of only 20% occurred or broncho- 
dilator use increased by 50%. We did not want to let our 
patients deteriorate further. 
Since compliance with regular medication particularly in 
asymptomatic patients is so often a problem it was pleasing 
to see such a high level of compliance in this study. Few 
patients took less than 75% of their prescribed medication. 
Probably, however, compliance was favourably influenced 
by the fact that the patients had to fill in a diary. It can be 
expected that a once-daily regimen can yield a better 
compliance than a twice-daily regimen, but that could not 
be investigated in the present study, since both groups had 
to inhale twice daily. 
A maintenance dose of 0.4 mg is usually advised for 
inhaled steroids; we choose a dose of 0.2 mg daily because 
by Turbuhaler half of the dose can be given (14). Despite 
lowering the steroid dose from on average 0.34 to exactly 
0.2 mg daily no deterioration occurred. This indicates 
that the patients were (slightly) overtreated in the run-in 
period and/or confirms the relevance of the two-fold lung 
deposition figure for Turbuhaler (12,13). From the present 
data, we do not conclude that all asthmatic patients can be 
treated with all inhaled steroids once daily. Local pharma- 
cokinetics can be quite different (18). For budesonide, most 
but not all studies showed that, in patients with moderate to 
severe asthma, four times daily administration is superior to 
twice-daily treatment (5-7,19). In cases with mild to 
moderate disease, not only can the total daily dose be lower 
(20) but the dosing frequency can apparently be reduced as 
well (8,9,19,21). Only one study (10) showed long-term 
asthma control to be inferior during the once-daily budeso- 
nide treatment compared with twice-daily treatment, but 
with equal effect on lung function. 
In conclusion, this study confirms the hypothesis that 
once-daily, low-dose inhaled budesonide can replace twice- 
daily administration in the successful management of 
patients with mild asthma. At a dosage of 0.2 mg once daily 
patients with mild, well-controlled asthma can be main- 
tained on this regime. This provides general practitioners 
with extra treatment flexibility in order to provide the 
therapy most suitable for their patients. 
Acknowledgements 
The authors wish to thank the 18 GPs who participated in 
this study. This study was supported and financed by Astra 
Pharmaceutics, The Netherlands. 
References 
1. British Asthma Guidelines Coordinating Committee. 
British guidelines on asthma management: 1995 review 
and position statement. Thorax 1997; 52: Sl-S24. 
2. Van der Waart MAC, Dekker FW, Nijhoff S et al. 
NHG-Standaard Cara bij Volwassen: Behandeling 
(Dutch guidelines for the management of asthma). 
Huisarts Wet 1992; 35: 437443. 
3. Laitinen LA, Laitinen A, Haahtela T. A comparative 
study of the effects of an inhaled corticosteroid, 
budesonide and a beta-2-agonist, terbutaline, on air- 
way inflammation in newly diagnosd asthma: a rand- 
omized, double blind, parallel group controlled trial. 
J Allergy Clin Immunol 1992; 90: 3042. 
4. Homedes A. Do we know how to influence patient’s 
behaviour? Tips to improve patients’ adherence. Fum 
Pratt 1991; 8: 412423. 
5. Toogood JH, Baskerville JC, Jennings B, Lefcoe NM, 
Lohansson SA. Influence of dosing frequency and 
schedule on the response of chronic asthmatics to the 
aerosol steroid budesonide. J Allergy Clin Immunol 
1982;’ 70: 288298. 
6. Malo JL, Castier A, Merland N, Gherro H, Burek A, 
Morris J, Jennings BH. Four times a day dosing 
frequency is better than a twice a day regimen in 
subjects requiring a high dose inhaled steroid, budeso- 
nide, to control moderate to severe asthma. Am Rev 
Respir Dis 1989; 140: 624628. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
ONCE-DAILY BUDESONIDE IN MILD ASTHMA 425 
Nyholm E, Frame MH, Cayton RM. Therapeutic 
advantage of twice daily over four daily budesonide 
Turbuhaler compared with placebo as initial prophy- 
lactic therapy for asthma. Respir Med 1994; 88: 
293-299. 
Campbell LM, Watson DG, Venable TL, Taylor MD, 
Richardson PDI. Once daily budesonide Turbuhaler 
compared with placebo as initial prophylactic therapy 
for asthma. Br J Clin Res 1991; 2: 111-122. 
Jones AH, Langdon CG, Lee PS et al. Pulmicort 
Turbohaler once daily as initial prophylactic therapy 
for asthma. Respir Med 1994; 88: 292-299. 
Weiner P, Weiner M, Azgad Y. Long term clinical 
comparison of single versus twice daily administration 
of inhaled budesonide in moderate asthma. Thorax 
1995; 50: 127G-1273. 
McGivern DV, Ward M, MacFarlane JT, Roderick 
Smith WH. Failure of once daily inhaled corticosteroid 
treatment to control chronic asthma. Thorax 1984; 39: 
933-934. 
Thorsson L, Edsbacker S, Conradson TB. Lung depo- 
sition of budesonide from Turbuhaler is twice that from 
a pressurised metered dose inhaler (pMDI). Eur Respir 
J 1994; 7: 183944. 
Borgstrom L, Newman S, Weisz A, Moren F. Pulmon- 
ary deposition of inhaled terbutaline: comparison of 
scanning gamma camera and urinary excretion meth- 
ods. J Pharm Sci 1992; 81: 753-755. 
Agertoft L, Pederson S. Importance of the inhalation 
device on the effect of budesonide. Arch Disc Childhood 
1993; 69: 130-3. 
Quanjer PH, Tammeling GG, Coates CE, Pedersen 0, 
Peslin R, Yernault GC. Lung volumes and forced 
ventilatory flow: official statement of the European 
Respiratory Society. Eur Respir J 1993; 6: (S16): 540. 
Jones B, Jarvis P, Lewis JA, Ebbitt AF. Trials to assess 
equivalence: the importance of rigorous methods. Br 
MedJ 1996;313: 36-39. 
Boe J, Rosenhall L, Alton M et al. Comparison of 
dose-response effects of inhaled beclomethasone dipro- 
pionate and budenoside in the management of asthma. 
Allergy 1989; 44: 349-355. 
Miller-Larsson A, Mattson H, Ohlsson S, Hjertberg E, 
Tunek A, Dahlback M. Brattsand R. Prolonged release 
from the airways tissue of glucocorticoids budesonide 
and fluticasone proprionate as compared to beclo- 
methasone diproprionate and hydrocortisone. Am J 
Respir Crit Care Med 1994; 149 S(4-2): A466. 
Malo JL, Cartier A, Ghezzo H, Trudeau C, Morris J, 
Jennings B. Comparison of four-times-a-day and twice- 
a-day dosing regimens in subjects requiring 1200 mcg 
or less of budesonide to control mild to moderate 
asthma. Respir Med 1995; 89: 531-543. 
20. Lorenzen S, Boe J, Eriksson G, Persson G. Use of 
inhaled corticosteroids in patients with mild asthma. 
Thorax 1990; 45: 733-735. 
21. Stiksa G, Glennow C. Once daily inhalation of budeso- 
nide in the treatment of chronic asthma: a clinical 
comparison. Ann Allerg,v 1985; 55: 49-51. 
